As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies for chronic conditions such as diabetes, arthritis, and hormone replacement therapy, drug developers are showing increased interest in routes of administration that are patient-friendly and cost-effective. A recent survey by Greystone concludes that intranasal administration is well positioned to take advantage of these trends and to evolve into a significant role in the future of pharmaceutical development and commercialization.
